Clinical Trial Update: Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating sintilimab combined with anlotinib as second-line or later therapy for extensive disease small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive Disease Small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Extensive Disease Small Cell Lung Cancer | Phase 2 | Status: COMPLETED